Tvardi Therapeutics Inc (TVRD)

08:11 AM

Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN

08:11 AM

May 22, 2026

Tvardi Therapeutics Q1 2026 Earnings: Narrower-than-expected loss as pipeline advancesEarnings Manipulation Risk - Newser

May 22, 2026

May 21, 2026

Tvardi Therapeutics to Participate in Upcoming Investor Events - Yahoo Finance

May 21, 2026

May 17, 2026

What Tvardi Therapeutics (TVRD)'s +1.01% Jump Means for Investors 2026-05-17Market Neutral Pair - Newser

May 17, 2026

May 14, 2026

[EFFECT] Tvardi Therapeutics, Inc. SEC Filing - Stock Titan

May 14, 2026

May 12, 2026

JonesTrading Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo

May 12, 2026

May 10, 2026

Number of shareholders of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView

May 10, 2026

May 08, 2026

593,758 resale shares by Tvardi Therapeutics (NASDAQ: TVRD) post‑merger - Stock Titan

May 08, 2026

May 08, 2026

Tvardi Therapeutics 4Q Research and Development Expenses $4.9M >TVRD - Moomoo

May 08, 2026

May 08, 2026

Tvardi Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 08, 2026

May 08, 2026

Tvardi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 08, 2026

May 08, 2026

MSN Money - MSN

May 08, 2026

May 08, 2026

Tvardi Therapeutics 1Q 2026: Revenue ($6.81M), Net income ($6.8M), EPS ($0.73) — 10-Q Summary - TradingView

May 08, 2026

May 08, 2026

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update - The Manila Times

May 08, 2026

May 08, 2026

Tvardi Therapeutics: Net loss narrowed to $6.8M, but continued operations depend on securing additional funding - TradingView

May 08, 2026

May 08, 2026

Tvardi Therapeutics: Net loss narrowed in Q1 2026 as clinical milestones for TTI-109 and TTI-101 approach - TradingView

May 08, 2026

May 08, 2026

Tvardi: Q1 Earnings Snapshot - marketscreener.com

May 08, 2026

May 08, 2026

Tvardi Therapeutics (NASDAQ: TVRD) posts Q1 2026 loss and warns on going concern - Stock Titan

May 08, 2026

May 08, 2026

Tvardi Therapeutics (NASDAQ: TVRD) narrows Q1 loss and targets 2026 STAT3 trial readouts - Stock Titan

May 08, 2026

May 08, 2026

Two biotech readouts ahead as Tvardi says cash lasts into Q4 - Stock Titan

May 08, 2026

May 08, 2026

The key risks discussed in Tvardi Therapeutics (TVRD) earnings | Q4 2025: EPS Misses ViewsRevenue Report - Newser

May 08, 2026

May 02, 2026

Tvardi Therapeutics Files $200 Million Mixed Shelf - Moomoo

May 02, 2026

May 01, 2026

Tvardi Therapeutics (NASDAQ: TVRD) registers $200M shelf, $12.5M ATM - Stock Titan

May 01, 2026

Apr 29, 2026

Is Tvardi Therapeutics (TVRD) stock breaking out | Q4 2025: EPS Misses EstimatesInvestment Signal Network - Newser

Apr 29, 2026

Apr 29, 2026

Tvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50 - MSN

Apr 29, 2026

Apr 26, 2026

TVRD Price Today: Tvardi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 26, 2026

Apr 24, 2026

Tvardi Therapeutics posts 18.3% downside EPS miss amid clinical trial costsEarnings Forecast - Newser

Apr 24, 2026